iTeos Therapeutics/$ITOS

13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX

About iTeos Therapeutics

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

Ticker

$ITOS
Primary listing

Industry

Biotechnology

Employees

173

ISIN

US46565G1040

ITOS Metrics

BasicAdvanced
$391M
-
-$3.09
1.43
-

What the Analysts think about ITOS

Analyst ratings (Buy, Hold, Sell) for iTeos Therapeutics stock.

Bulls say / Bears say

iTeos Therapeutics maintains a strong cash position of $624.3 million as of March 31, 2025, providing financial stability and runway through 2027. (iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates)
The company is exploring potential asset sales, including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1, which could unlock shareholder value. (iTeos Therapeutics Announces Intent to Wind Down Operations and Explore Asset Sales to Maximize Shareholder Value)
Institutional investors like RA Capital Management and Boxer Capital have shown confidence by leading a $120 million registered direct offering, strengthening iTeos' financial position. (iTeos Therapeutics Announces $120 Million Registered Direct Offering)
iTeos and GSK have terminated the development of their experimental lung cancer therapy, belrestotug, after it failed to significantly improve progression-free survival in mid-stage trials. (iTeos, GSK discontinue lung cancer therapy development)
The company has announced its intention to wind down operations, focusing on selecting the best path to deliver near-term value to shareholders, indicating potential challenges in its pipeline. (iTeos Therapeutics Announces Its Intention to Wind Down Operations)
JPMorgan Chase & Co. has lowered its price target for iTeos Therapeutics from $22.00 to $15.00, reflecting reduced expectations for the company's stock performance. (JPMorgan Chase & Co. Has Lowered Expectations for iTeos Therapeutics (NASDAQ:ITOS) Stock Price)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.

ITOS Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ITOS Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ITOS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs